Atacand candesartan cilexetil: Phase III data

In the 4-year, double-blind, international Phase III DIRECT-Protect 2 trial in 1,905 Type II diabetics with mild to moderately severe retinopathy, once-daily Atacand missed the primary endpoint of sig...